This product is for research purposes only. Not for human consumption.
Purity: >98% (HPLC verified)
Formulation: Lyophilized powder
Molecular Formula: C236H347N57O73
Molecular Weight: 5199.7 g/mol
CAS Number: N/A
PubChem CID: N/A
Mazdutide
Overview
Mazdutide is a novel dual GLP-1/glucagon receptor agonist under development for obesity and metabolic disease treatment. This balanced co-agonist approach leverages both GLP-1 effects (appetite suppression, improved glycemic control) and glucagon effects (increased energy expenditure) to provide enhanced weight loss efficacy.
Mechanism of Action
Mazdutide activates both GLP-1 and glucagon receptors with balanced potency. GLP-1 activation reduces appetite, slows gastric emptying, and improves insulin secretion. Glucagon activation increases energy expenditure, enhances lipolysis, and promotes fat oxidation. This dual mechanism provides complementary metabolic benefits for weight management.
Research Findings
Phase 2 clinical trials have demonstrated Mazdutide's significant weight loss efficacy, with studies showing substantial reductions in body weight and improvements in metabolic parameters. Research indicates it may provide weight loss comparable to or exceeding other dual agonists while maintaining good tolerability.
Research Applications
- Obesity treatment research
- Metabolic syndrome studies
- Type 2 diabetes research
- Dual incretin therapy research
- Energy expenditure studies
- Body composition research
Safety Profile
Mazdutide is currently in clinical development with ongoing safety evaluation. Early trial data suggests a safety profile consistent with other incretin-based therapies, with gastrointestinal side effects being most common.
Scientific References
Research Use Only
This product is intended for research purposes only and is not for human consumption, therapeutic use, or diagnostic applications. Please ensure compliance with all applicable regulations and institutional guidelines.